The anti-LAG-3 antibody BMS-986016 is currently being used in phase I and phase II clinical trials in combination with nivolumab in subjects with relapsed or refractory HL, and relapsed or refractory diffuse large B cell lymphoma (DLBCL) (NCT02061761) or as a single drug in lymphoma (NCT03489369). The gene discussed is LAG3; the disease is Hodgkins lymphoma.